Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Tolerance and acceptability of an efavirenz-based regimen in 740 adults (predominantly women) in West Africa
Journal of Acquired Immune Deficiency Syndromes, Volume 42, No. 1, Year 2006
Notification
URL copied to clipboard!
Description
In sub-Saharan Africa, the position of efavirenz as a first-line nonnucleoside reverse transcriptase inhibitor remains to be discussed. We report here the 6-month efficacy and tolerance of an efavirenz-containing highly active antiretroviral therapy in a large cohort of HIV-1-infected adults.Seven hundred forty highly active antiretroviral therapy-naive adults (74% women; 14% with positive serum HBs antigen and 21% with abnormal baseline transaminase value) started zidovudine + lamivudine + efavirenz. At month 6, 1.2% of them were dead, 87% had undetectable viral load, and 7% had abnormal transaminase value. From months 1 to 6, the percentage of women who were actually using a contraceptive method increased from 58% to 80% (65% intramuscular progesterone and 35% oral estrogen/progesterone combination). The incidence of pregnancy was 2.6/100 woman-years (95% confidence interval, 0.67-4.51), and 86% of pregnant women voluntarily interrupted the pregnancy with no intervention on our part. Before month 6, only 0.8% of patients permanently discontinued efavirenz for severe adverse effects (neurologic, 0.6%; cutaneous, 0.1%; and hepatic, 0.1%). The leading cause of severe morbidity was tuberculosis.Considering the very high hepatic and cutaneous tolerance, efavirenz could be considered as a valuable first-line drug for women of childbearing age who agree to use contraception in sub-Saharan Africa, provided that the risk of teratogenicity should be closely monitored. Copyright © 2006 by Lippincott Williams & Wilkins.
Authors & Co-Authors
Danel, Christine
Cote D'ivoire, Abidjan
Programme Pac-ci
Moh, Raoul D.
Cote D'ivoire, Abidjan
Programme Pac-ci
Anzian, Amani
Cote D'ivoire, Abidjan
Programme Pac-ci
Abo, Yao
Cote D'ivoire, Abidjan
Programme Pac-ci
Chenal, Henri
Cote D'ivoire, Abidjan
Programme Pac-ci
Guéhi, Calixte
Cote D'ivoire, Abidjan
Programme Pac-ci
Gabillard, Delphine
Cote D'ivoire, Abidjan
Programme Pac-ci
France, Paris
Inserm
Sorho, Souleymane
Cote D'ivoire, Abidjan
Programme Pac-ci
Rouet, François
Cote D'ivoire, Abidjan
Programme Pac-ci
Cote D'ivoire, Abidjan
Centre Hospitalier Universitaire de Treichville
Eholié, Serge Paul
Cote D'ivoire, Abidjan
Programme Pac-ci
Cote D'ivoire, Abidjan
Centre Hospitalier Universitaire de Treichville
Anglaret, Xavier
Cote D'ivoire, Abidjan
Programme Pac-ci
France, Paris
Inserm
Statistics
Citations: 53
Authors: 11
Affiliations: 3
Identifiers
Doi:
10.1097/01.qai.0000219777.04927.50
ISSN:
15254135
Research Areas
Health System And Policy
Infectious Diseases
Maternal And Child Health
Sexual And Reproductive Health
Study Design
Randomised Control Trial
Cohort Study
Study Locations
Multi-countries
Participants Gender
Female